Hepatitis C Virus (HCV) is a viral infection that causes liver inflammation, sometimes leading to serious liver damage. It is caused by the hepatitis C virus (HCV) and is a major cause of liver cancer. When the liver is inflamed or damaged, its function can be affected. Hepatitis C Virus (HCV) is diagnosed based on the patient’s medical history, a physical exam, and blood tests. If a viral infection is confirmed, doctors may suggest additional tests to check the condition of the liver. A simple blood test can be carried out to test for anti-HCV antibodies that identify people who have been infected with the virus. Blood tests for HCV include screening tests for antibodies to the HCV virus, HCV RNA tests, Genotype tests, etc.
The goal of hepatitis C treatment is a cure. HCV can be treated with antiviral medicines that attack the virus and can cure the disease in most cases. Several newer medicines, called direct-acting antiviral medicines, have also been approved to treat HCV since 2013. The four classes of DAAs include NS5B nucleotide inhibitors, NS5B non-nucleoside inhibitors, NS5A replication complex inhibitors, and NS3/4A protease inhibitors (PI).
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/hepatitis-c-virus-market
The Hepatitis C Virus (HCV) market report also covers emerging drugs, current treatment practices, Hepatitis C Virus (HCV) market share of the individual therapies, current and forecasted Hepatitis C Virus (HCV) Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Hepatitis C Virus (HCV) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Hepatitis C Virus (HCV) Market Key Facts
-
In the year 2017, the total prevalent case of Hepatitis C Virus (HCV) was 8,257,162 cases in the 7MM. These cases are expected to grow with minimal CAGR in the study period 2017–2030.
-
As per the DelveInsight estimates, the US, in 2017, accounted for 3,251,471 prevalent cases of Hepatitis C Virus (HCV). These cases are expected to grow with a minimal CAGR in the study period 2017–2030.
-
in the United Kingdom, the total Gender-specific cases of Hepatitis C Virus (HCV) were 71,941 cases for males and 52,417 cases for females in the year 2017.
-
Germany accounted for 221,634 diagnosed cases of Hepatitis C Virus (HCV) in 2017 among 7MM.
Key Benefits of Hepatitis C Virus (HCV) Market Report
-
Hepatitis C Virus (HCV) market report provides an in-depth analysis of Hepatitis C Virus (HCV) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Hepatitis C Virus (HCV) market report will help in developing business strategies by understanding the Hepatitis C Virus (HCV) Market trends & developments, key players, and future market competition that will shape and drive the Hepatitis C Virus (HCV) market in the upcoming years.
-
The Hepatitis C Virus (HCV) market report covers Hepatitis C Virus (HCV) current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Hepatitis C Virus (HCV) market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Hepatitis C Virus (HCV) Market
The Hepatitis C Virus (HCV) market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Hepatitis C Virus (HCV) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Hepatitis C Virus (HCV) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Hepatitis C Virus (HCV) Epidemiology
The Hepatitis C Virus (HCV) epidemiology section covers insights about the historical and current Hepatitis C Virus (HCV) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Hepatitis C Virus (HCV) Drugs Uptake and Key Market Players
The Hepatitis C Virus (HCV) Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatitis C Virus (HCV) market or expected to get launched in the market during the study period. The analysis covers Hepatitis C Virus (HCV) market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The emerging therapies which are under development will provide efficient therapeutic approaches with novel mechanisms of action for the treatment of patients affected with Hepatitis C Virus (HCV).
Hepatitis C Virus (HCV) Companies:
Cocrystal Pharma
Atea Pharmaceuticals
PRISM Pharma
Ohara Pharmaceuticals
AbbVie
Gilead Sciences
Merck
And many others.
Hepatitis C Virus (HCV) therapies covered in the report include:
CC-31244 (CDI-31244)
AT-527 and AT-777 (now combined as AT-787)
PRI-724 (OP-724)
HCVax (Therapeutic HCV vaccine)
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Hepatitis C Virus (HCV) Competitive Intelligence Analysis
4. Hepatitis C Virus (HCV) Market Overview at a Glance
5. Hepatitis C Virus (HCV) Disease Background and Overview
6. Hepatitis C Virus (HCV) Patient Journey
7. Hepatitis C Virus (HCV) Epidemiology and Patient Population
8. Hepatitis C Virus (HCV) Treatment Algorithm, Current Treatment, and Medical Practices
9. Hepatitis C Virus (HCV) Unmet Needs
10. Key Endpoints of Hepatitis C Virus (HCV) Treatment
11. Hepatitis C Virus (HCV) Marketed Products
12. Hepatitis C Virus (HCV) Emerging Therapies
13. Hepatitis C Virus (HCV) Seven Major Market Analysis
14. Attribute Analysis
15. Hepatitis C Virus (HCV) Market Outlook (7 major markets)
16. Hepatitis C Virus (HCV) Access and Reimbursement Overview
17. KOL Views on the Hepatitis C Virus (HCV) Market.
18. Hepatitis C Virus (HCV) Market Drivers
19. Hepatitis C Virus (HCV) Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Related Reports
Hepatitis C Virus (HCV) Epidemiology Forecast
DelveInsight’s Hepatitis C Virus (HCV) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hepatitis C Virus (HCV) in the seven major markets.
Latest BioPharma Blog –
Chronic Refractory Cough Therapeutics Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/